190 related articles for article (PubMed ID: 37434334)
1. Elranatamab: a new promising BispAb in multiple myeloma treatment.
Grosicki S; Bednarczyk M; Kociszewska K
Expert Rev Anticancer Ther; 2023; 23(8):775-782. PubMed ID: 37434334
[TBL] [Abstract][Full Text] [Related]
2. Elranatamab: First Approval.
Dhillon S
Drugs; 2023 Nov; 83(17):1621-1627. PubMed ID: 37924427
[TBL] [Abstract][Full Text] [Related]
3. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
4. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.
Mutlu YG; Yıgıt Kaya S; Maral S; Melek E; Baslar Z; Kaynar L; Sevindik OG
Front Immunol; 2023; 14():1276295. PubMed ID: 37901215
[TBL] [Abstract][Full Text] [Related]
5. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Bahlis NJ; Costello CL; Raje NS; Levy MY; Dholaria B; Solh M; Tomasson MH; Damore MA; Jiang S; Basu C; Skoura A; Chan EM; Trudel S; Jakubowiak A; Gasparetto C; Chu MP; Dalovisio A; Sebag M; Lesokhin AM
Nat Med; 2023 Oct; 29(10):2570-2576. PubMed ID: 37783970
[TBL] [Abstract][Full Text] [Related]
6. Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma.
Rais T; Khan A; Riaz R
Rare Tumors; 2023; 15():20363613231207483. PubMed ID: 37840703
[TBL] [Abstract][Full Text] [Related]
7. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
8. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
9. A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.
Mol I; Hu Y; LeBlanc TW; Cappelleri JC; Chu H; Nador G; Aydin D; Schepart A; Hlavacek P
Curr Med Res Opin; 2024 Feb; 40(2):199-207. PubMed ID: 38078866
[TBL] [Abstract][Full Text] [Related]
10. Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3.
Mohty M; Bahlis NJ; Nooka AK; DiBonaventura M; Ren J; Conte U
Br J Haematol; 2024 May; 204(5):1801-1810. PubMed ID: 38420657
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.
Metelo AM; Jozwik A; Luong LA; Dominey-Foy D; Graham C; Attwood C; Inam S; Dunlop A; Sanchez K; Cuthill K; Rice C; Streetly M; Bentley T; Boldajipour B; Sommer C; Sasu B; Benjamin R
Cancer Res Commun; 2022 Mar; 2(3):158-171. PubMed ID: 36874402
[TBL] [Abstract][Full Text] [Related]
12. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Tai YT; Anderson KC
Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
[No Abstract] [Full Text] [Related]
13. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.
Costa LJ; LeBlanc TW; Tesch H; Sonneveld P; Kyle RP; Sinyavskaya L; Hlavacek P; Meche A; Ren J; Schepart A; Aydin D; Nador G; DiBonaventura MD
Future Oncol; 2024 Feb; ():. PubMed ID: 38415370
[TBL] [Abstract][Full Text] [Related]
14. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Lesokhin AM; Tomasson MH; Arnulf B; Bahlis NJ; Miles Prince H; Niesvizky R; Rodrίguez-Otero P; Martinez-Lopez J; Koehne G; Touzeau C; Jethava Y; Quach H; Depaus J; Yokoyama H; Gabayan AE; Stevens DA; Nooka AK; Manier S; Raje N; Iida S; Raab MS; Searle E; Leip E; Sullivan ST; Conte U; Elmeliegy M; Czibere A; Viqueira A; Mohty M
Nat Med; 2023 Sep; 29(9):2259-2267. PubMed ID: 37582952
[TBL] [Abstract][Full Text] [Related]
15. A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma.
Xiong M; Liu R; Lei X; Fan D; Lin F; Hao W; Yuan X; Yang Y; Zhang X; Ye Z; Lu Y; Zhang Y; Wang J; Xiong D
J Immunother; 2022 Feb-Mar 01; 45(2):78-88. PubMed ID: 34711791
[TBL] [Abstract][Full Text] [Related]
16. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies as an addition to current myeloma therapy strategies.
Jullien M; Touzeau C; Moreau P
Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
[TBL] [Abstract][Full Text] [Related]
18. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma.
Mol I; Hu Y; LeBlanc TW; Cappelleri JC; Chu H; Nador G; Aydin D; Schepart A; Hlavacek P
Leuk Lymphoma; 2024 May; 65(5):660-668. PubMed ID: 38347747
[TBL] [Abstract][Full Text] [Related]
19. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
20. Antibody therapies for multiple myeloma.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
Expert Opin Biol Ther; 2020 Mar; 20(3):295-303. PubMed ID: 31944131
[No Abstract] [Full Text] [Related]
[Next] [New Search]